In short
This article explores the use of Pegenzileukin, also known as SAR444245, in clinical trials for the treatment of relapsed or refractory multiple myeloma. As part of a larger study investigating various drug combinations, Pegenzileukin is being tested in combination with Isatuximab to evaluate its effectiveness and safety in patients who have not responded to previous treatments or have experienced a recurrence of their disease.
At a glance
- Drug Name
- Pegenzileukin (SAR444245)
- Condition Treated
- Relapsed or Refractory Multiple Myeloma (RRMM)
- Combination Therapy
- Used with Isatuximab
- Administration
- Intravenous infusion every two weeks (Q2W)
- Trial Structure
- Part 1: Dose finding and optimization; Part 2: Dose expansion
- Primary Outcome
- Overall Response Rate (ORR)
- Treatment Duration
- Up to approximately 28 months
- Safety Assessments
- Adverse events, serious adverse events, laboratory parameters
What is Pegenzileukin?
Pegenzileukin, also known by its research name SAR444245, is a new drug being studied for the treatment of certain blood cancers. It is classified as a novel agent, which means it's a relatively new medication with a unique way of working in the body. Pegenzileukin is given to patients through an intravenous (IV) infusion, which means it's delivered directly into the bloodstream through a vein.
What Condition Does Pegenzileukin Target?
The primary focus of the current research involving Pegenzileukin is on treating relapsed or refractory multiple myeloma (RRMM). Multiple myeloma is a type of blood cancer that affects plasma cells, which are a crucial part of the immune system. When a patient has relapsed or refractory multiple myeloma, it means that their cancer has either returned after treatment or hasn't responded well to previous treatments.
How is Pegenzileukin Used?
In the ongoing clinical trial, Pegenzileukin is being tested in combination with another drug called Isatuximab. This combination approach is common in cancer treatment, as it often leads to better results than using a single drug alone. The treatment schedule for Pegenzileukin in this trial is as follows:
- Pegenzileukin is given every two weeks (Q2W) through an IV infusion
- Isatuximab is given weekly for the first 4 weeks, then every two weeks after that
Current Clinical Trial
Pegenzileukin is currently being studied in a clinical trial known as the UMBRELLA trial. This trial is testing several new drugs in combination with Isatuximab for treating relapsed or refractory multiple myeloma. The part of the trial focusing on Pegenzileukin is called Substudy 04. This substudy is divided into two main parts:
- Part 1 - Dose Finding: This phase aims to determine the safest and most effective dose of Pegenzileukin. Researchers will test up to three different dose levels.
- Part 2 - Dose Expansion: Once the best dose is determined, more patients will be treated with this dose to further evaluate its effectiveness and safety.
Potential Benefits
While it's too early to know for certain, researchers hope that Pegenzileukin, when combined with Isatuximab, might offer several potential benefits for patients with relapsed or refractory multiple myeloma:
- Improved response rates to treatment
- Longer-lasting remissions
- Better quality of life for patients
- A new option for patients who haven't responded well to other treatments
Possible Side Effects
As with any new medication, understanding the potential side effects of Pegenzileukin is an important part of the clinical trial. The researchers will be closely monitoring patients for any adverse reactions. Some of the things they'll be watching for include:
- Treatment-emergent adverse events (TEAEs)
- Serious adverse events (SAEs)
- Changes in laboratory test results
- Changes in vital signs
It's important to note that not all patients will experience side effects, and the severity can vary from person to person. If you're considering participating in a clinical trial or starting a new treatment, always discuss potential risks and benefits with your healthcare provider.